Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.
Angwin C, Jenkinson C, Jones A, Jennison C, Henley W, Farmer A, Sattar N, Holman RR, Pearson E, Shields B, Hattersley A; MASTERMIND consortium. Angwin C, et al. Among authors: sattar n. BMJ Open. 2020 Dec 21;10(12):e042784. doi: 10.1136/bmjopen-2020-042784. BMJ Open. 2020. PMID: 33371044 Free PMC article.
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR, Bethel MA, Chan JC, Chiasson JL, Doran Z, Ge J, Gerstein H, Huo Y, McMurray JJ, Ryden L, Liyanage W, Schröder S, Tendera M, Theodorakis MJ, Tuomilehto J, Yang W, Hu D, Pan C; ACE Study Group. Holman RR, et al. Am Heart J. 2014 Jul;168(1):23-9.e2. doi: 10.1016/j.ahj.2014.03.021. Epub 2014 Apr 5. Am Heart J. 2014. PMID: 24952856 Clinical Trial.
Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease.
Yaghootkar H, Lotta LA, Tyrrell J, Smit RA, Jones SE, Donnelly L, Beaumont R, Campbell A, Tuke MA, Hayward C, Ruth KS, Padmanabhan S, Jukema JW, Palmer CC, Hattersley A, Freathy RM, Langenberg C, Wareham NJ, Wood AR, Murray A, Weedon MN, Sattar N, Pearson E, Scott RA, Frayling TM. Yaghootkar H, et al. Among authors: sattar n. Diabetes. 2016 Aug;65(8):2448-60. doi: 10.2337/db15-1671. Epub 2016 Apr 26. Diabetes. 2016. PMID: 27207519 Free PMC article.
Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study.
Aucott LS, Philip S, Avenell A, Afolabi E, Sattar N, Wild S; Scottish Diabetes Research Network Epidemiology Group. Aucott LS, et al. Among authors: sattar n. BMJ Open. 2016 Jul 26;6(7):e010836. doi: 10.1136/bmjopen-2015-010836. BMJ Open. 2016. PMID: 27466237 Free PMC article.
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH, Stewart C, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N; DIRECT consortium group. Preiss D, et al. Among authors: sattar n. Diabetes Obes Metab. 2017 Mar;19(3):356-363. doi: 10.1111/dom.12826. Epub 2016 Dec 28. Diabetes Obes Metab. 2017. PMID: 27862873 Free PMC article. Clinical Trial.
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group. Petrie JR, et al. Among authors: sattar n. Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609. doi: 10.1016/S2213-8587(17)30194-8. Epub 2017 Jun 11. Lancet Diabetes Endocrinol. 2017. PMID: 28615149 Free PMC article. Clinical Trial.
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group. Holman RR, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917545 Free article. Clinical Trial.
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.
Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium. Dennis JM, et al. Among authors: sattar n. Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31. Diabetes Care. 2018. PMID: 29386249 Free PMC article.
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.
Griffin SJ, Bethel MA, Holman RR, Khunti K, Wareham N, Brierley G, Davies M, Dymond A, Eichenberger R, Evans P, Gray A, Greaves C, Harrington K, Hitman G, Irving G, Lessels S, Millward A, Petrie JR, Rutter M, Sampson M, Sattar N, Sharp S. Griffin SJ, et al. Among authors: sattar n. Health Technol Assess. 2018 Apr;22(18):1-64. doi: 10.3310/hta22180. Health Technol Assess. 2018. PMID: 29652246 Free PMC article. Clinical Trial.
1,540 results